CD30 [Ber-H2] (ready-to-use)

Ber-H2

BALB/C mice were injected with L428 cell line cells.

This antibody reacts with mononuclear cells in Hodgkin lymphoma Reed-Sternberg cells and most anaplastic large cell lymphomas. It stains large cells localized around the B cell in the lymphoid tissues. This antibody stains the cell surface and the golgi region in the cells.

Type I membrane protein (long isoform); cytoplasmic (short isoform).

PBS with sodium azide

Type I membrane protein (long isoform); cytoplasmic (short isoform). CD30 is a type I transmembrane glycoprotein of the TNF receptor superfamily. CD30 was originally identified as a cell surface antigen of Hodgkins and Reed-Sternberg cells using monoclonal antibody Ki-1. The ligand for CD30 is CD30L (CD153). The binding of CD30 to CD30L mediates pleiotropic effects including cell proliferation activation differentiation and apoptotic cell death. CD30 has a critical role in the pathophysiology of Hodgkins disease and other CD30+ lymphomas. CD30 acts as a costimulatory molecule in thymic negative selection. In addition to its expression on Hodgkins and Reed- Sternberg cells CD30 is also found in some non-Hodgkins lymphomas (including Burkitts lymphomas) virus-infected T and B cells and on normal T and B cells after activation. In T cells CD30 expression is present on a subset of T cells that produce Th2-type cytokines and on CD4+/CD8+ thymocytes that coexpress CD45RO and the IL4 receptor.

Interacts with TRAF1 TRAF2 TRAF3 and TRAF5.

Isoform Short: Cytoplasm.

Most specific Hodgkin disease associated antigen.